China Medicine Corporation grated Australian patent for recombinant Aflatoxin Detoxifizyme

China Medicine Corporation announced today that it obtained a patent from Australia Patent Office for recombinant Aflatoxin Detoxifizyme (rADTZ). The patent is valid through January 13, 2025.

rADTZ is an innovative product that has the potential to detoxify aflatoxin (AFT), a potential cancer causing agent, in food and feed. It is a compound that is a derivation of aflatoxin-detoxifizyme (ADTZ), an extracellular enzyme. Developed by Guangzhou Co-Win Bioengineering Co., Ltd, a subsidiary of China Medicine, rADTZ can be used as an additive to remove aflatoxins from animal feed as well as other food products. The Company intends to develop rADTZ for this and other applications.

"We are proud to announce that we have achieved a major milestone in being granted a patent for rADTZ in Australia," said Mr. Senshan Yang, Chairman and CEO of China Medicine. "This is a major breakthrough for China Medicine and it opens up the opportunity to expand our business overseas," he added. China Medicine has already obtained a patent for rADTZ from the State Intellectual Property Office of China in early 2004.

China Medicine has performed laboratory experiment on rADTZ and has gathered important data to address technological challenges related to its development. The Company is currently testing rADTZ on animal feed and is scheduled to begin working with the Chinese Department of Agriculture on a large scale experiment in order to meet national standards and apply for production permits. Once the Company receives production permits, it expects to begin trial sales of rADTZ by the end of 2008.